Pages that link to "Q38407917"
Jump to navigation
Jump to search
The following pages link to Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial (Q38407917):
Displaying 50 items.
- Towards tumor immunodiagnostics (Q26738691) (← links)
- Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer (Q26745446) (← links)
- Marrow-Infiltrating Lymphocytes - Role in Biology and Cancer Therapy (Q26749560) (← links)
- Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab (Q26764879) (← links)
- Relevance of tumor-infiltrating lymphocytes in breast cancer (Q26795598) (← links)
- Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention (Q28067145) (← links)
- The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy (Q28076473) (← links)
- Translating neoadjuvant therapy into survival benefits: one size does not fit all. (Q30251738) (← links)
- Heterogeneity of CD8+ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies (Q30275647) (← links)
- Precision medicine in breast cancer: reality or utopia? (Q33809114) (← links)
- Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes (Q33814856) (← links)
- The Role of Neoadjuvant Trials in Drug Development for Solid Tumors (Q33886353) (← links)
- The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population (Q33915044) (← links)
- Antibody-supervised deep learning for quantification of tumor-infiltrating immune cells in hematoxylin and eosin stained breast cancer samples (Q36149520) (← links)
- A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray. (Q36186223) (← links)
- A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways (Q36231343) (← links)
- MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients (Q36545717) (← links)
- Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting (Q36673469) (← links)
- Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies (Q37075648) (← links)
- Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. (Q37160109) (← links)
- Repeated observation of immune gene sets enrichment in women with non-small cell lung cancer. (Q37190289) (← links)
- Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis (Q37536862) (← links)
- Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers (Q37536901) (← links)
- Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients (Q37544396) (← links)
- Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation (Q37593573) (← links)
- Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial (Q38373249) (← links)
- Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study (Q38376822) (← links)
- RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. (Q38387030) (← links)
- Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change af (Q38411841) (← links)
- Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions (Q38639746) (← links)
- HER2-positive breast cancer is lost in translation: time for patient-centered research (Q38648765) (← links)
- Clinical relevance of host immunity in breast cancer: from TILs to the clinic (Q38669465) (← links)
- Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge (Q38786102) (← links)
- Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication (Q38823649) (← links)
- The molecular basis of breast cancer pathological phenotypes (Q39175548) (← links)
- Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation (Q39321597) (← links)
- Advancing Immunotherapy in Metastatic Breast Cancer (Q39324161) (← links)
- De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance (Q39421814) (← links)
- Targeted Therapy and Immunosuppression in the Tumor Microenvironment (Q39441315) (← links)
- Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. (Q39638185) (← links)
- Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer (Q40284336) (← links)
- Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. (Q40521722) (← links)
- Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy (Q41189272) (← links)
- Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy (Q41545839) (← links)
- Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study. (Q41660755) (← links)
- Data integration from pathology slides for quantitative imaging of multiple cell types within the tumor immune cell infiltrate (Q41705524) (← links)
- Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer (Q42393214) (← links)
- Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial (Q42497114) (← links)
- Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time? (Q45070547) (← links)
- The Predictive and Prognostic Role of Stromal Tumor-infiltrating Lymphocytes in HER2-positive Breast Cancer with Trastuzumab-based Treatment: a Meta-analysis and Systematic Review (Q47109695) (← links)